Q-omics provides the consensus-scored NANOGP2 profile across patient tissues and cancer cell-line models. NANOGP2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, NANOGP2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, NANOGP2 RNA expression shows 6,786 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, LUSC, and TGCT as cancer lineages where NANOGP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOGP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOGP2 survival associations across molecular data types. NANOGP2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOGP2 RNA expression–survival associations across cancer types. High NANOGP2 expression shows unfavorable associations in DLBC, THYM, UCEC, COAD and READ, but favorable associations in LUSC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for NANOGP2 RNA expression.
This table summarizes NANOGP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NANOGP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOGP2 shows lower tumor expression in LUSC, KIRP, KICH and THCA and higher tumor expression in BRCA. The LUSC box plot shows higher NANOGP2 RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p = .003).
This table shows molecular features associated with NANOGP2 in patient tissues and cancer cell lines. In patient samples, NANOGP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
